MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management

Ola Landgren; Rafat Abonour; Dickran Kazandjian

doi:10.1053/j.seminhematol.2026.01.002

January 1, 2026Seminars in Hematology

MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management

View at Publisher

Ask AI

Bookmark

Share

Key Points

MRD-driven treatment enhances patient clinical management outcomes, leading to better overall care.
Key metrics indicate that achieving MRD can significantly alter treatment plans and decisions.
Analysis highlights the transition of MRD from an early endpoint for approval to a guiding principle in treatment.
Implications suggest that understanding MRD may improve personalized treatment approaches in multiple myeloma.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Observational analysis reveals that minimal residual disease (MRD) impacts treatment and clinical management in multiple myeloma, suggesting enhanced patient outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Landgren et al. (2026) studied this question.

synapsesocial.com/papers/69a75e53c6e9836116a28ca8 https://doi.org/10.1053/j.seminhematol.2026.01.002

View at Publisher

Ask AI

Bookmark

Share

MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management

Key Points

No abstract yet

Implication

Discussion

Cite This Study

MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

More related papers

More from Seminars in Hematology

Keep reading

More related papers

More from Seminars in Hematology